Advice
In the absence of a submission from the holder of the marketing authorisation.
darbepoetin alfa (Aranesp) is not recommended for use within NHS Scotland for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this formulation. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice28KB (PDF)
Medicine details
- Medicine name:
- Darbepoetin alfa (Aranesp®)
- SMC ID:
- 273/06
- Indication:
- Anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Non submission
- Status
- Superseded
- Date advice published
- 08 May 2006